Last Modified:
11/12/2023 9:48:36 AM
Medical Necessity Documentation:
Client Notes:
Patient Preparation:
Specimen Requirements:
1.0 mL Serum in a SST Gold Top Tube
Collection Instructions:
Minimum Volume:
0.5 mL
Transport & Storage: Temperature/Stability:
14 days Ambient
14 days Refrigerated
30 daysFrozen
Rejection Criteria:
microbially contaminated; gross hemolysis; grossly lipemic
Reference Range:
< 15 % of inibition
Critical Ranges:
Test Comments:
Methodology:
RIA
Clinical Significance:
Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.
Documentation:
Custom Panel:
No
PRODUCTION SCHEDULE
Turn Around Time:
3 to 6 days
Days Performed:
Sunday, Tuesday, Thursday
Sites Performed:
Quest - Chantilly to San Juan Capistrano
PHL Test Code:
ACRBA
EPIC Test Code:
LAB838
Send Out Test Code:
34459
Alternate Test Names:
Acetylcholine Receptor, Blocking; ACHR Blocking Antibody; Myasthenia Gravis Evaluation
Included Tests:
CPT Coding:
83519
Go back to the top of the page.